

Million A Tegenge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8571921/publications.pdf>

Version: 2024-02-01

22
papers

227
citations

1039880

9
h-index

1058333

14
g-index

22
all docs

22
docs citations

22
times ranked

321
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 189-197.	1.0	34
2	A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 545-556.	0.8	27
3	A first-generation physiologically based pharmacokinetic (PBPK) model of alpha-tocopherol in human influenza vaccine adjuvant. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 71, 353-364.	1.3	21
4	Opportunities and challenges for applying model-informed drug development approaches to gene therapies. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 286-290.	1.3	20
5	Pharmacokinetics and biodistribution of squalene-containing emulsion adjuvant following intramuscular injection of H5N1 influenza vaccine in mice. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 81, 113-119.	1.3	18
6	Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products. <i>Haemophilia</i> , 2017, 23, 705-711.	1.0	14
7	TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity. <i>AAPS Journal</i> , 2019, 21, 96.	2.2	13
8	Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence. <i>Antibodies</i> , 2020, 9, 24.	1.2	13
9	Comparative pharmacokinetic and biodistribution study of two distinct squalene-containing oil-in-water emulsion adjuvants in H5N1 influenza vaccines. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 108, 104436.	1.3	12
10	Age- and Bodyweight-dependent Allometric Exponent Model for Scaling Clearance and Maintenance Dose of Theophylline From Neonates to Adults. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 635-641.	1.0	10
11	Clinical Pharmacology Review of Plasma-derived and Recombinant Protein Products: CBER Experience and Perspectives on Model-informed Drug Development. <i>Haemophilia</i> , 2019, 25, e240-e246.	1.0	8
12	A bodyweight-dependent allometric exponent model for scaling clearance of clotting factor VIII and IX from infants to adults. <i>Haemophilia</i> , 2016, 22, e570-e573.	1.0	7
13	Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 877-884.	1.0	7
14	Dosing Considerations for Antibodies Against COVID-19. <i>Drugs in R and D</i> , 2021, 21, 1-8.	1.1	5
15	Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1567-1576.	1.6	4
16	Advancing the science of patient input throughout the regulatory decision-making process. <i>Learning Health Systems</i> , 2017, 1, e10032.	1.1	4
17	Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates. <i>International Immunopharmacology</i> , 2020, 80, 106192.	1.7	3
18	Spreadsheet-Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S108-S116.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Comparing clotting factors attributes across different methods of preference elicitation in haemophilia patients. <i>Haemophilia</i> , 2020, 26, 817-825.	1.0	2
20	Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 97, 57-62.	1.3	1
21	Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction. <i>International Immunopharmacology</i> , 2020, 82, 106358.	1.7	1
22	Model-Based Evaluation of Linear Limited and Bayesian Sparse Sampling for Therapeutic Monitoring of Recombinant Coagulation Factor IX. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1453-1460.	1.0	0